Enantat 400

Enantat 400 Dragon Pharma — Overview

Enantat 400 Dragon Pharma is testosterone enanthate at 400 mg per mL — the same compound as Enantat 250, reformulated at a higher concentration. The practical result is a significantly reduced injection volume for any given weekly dose: 500 mg per week requires 1.25 mL at 400 mg/mL versus 2.0 mL at 250 mg/mL; 800 mg per week requires 2.0 mL versus 3.2 mL. Everything else — the enanthate ester, the 8–10 day active life, the aromatization profile, the PCT timing — is identical to the 250 mg/mL version.

This page covers the pharmacology of testosterone enanthate, the practical case for the 400 mg/mL format, combination options using Dragon Pharma products, side effect management, and PCT.

About the Compound: Testosterone Enanthate at 400 mg/mL

Testosterone enanthate is the C8 fatty acid ester of testosterone. After intramuscular injection the ester is cleaved by tissue esterases, releasing free testosterone over 8–10 days. The plasma half-life of the released testosterone is approximately 4.5 days, and twice-weekly (E3.5D) injections are generally preferred over once-weekly (E7D) to minimize the peak-to-trough fluctuation in blood testosterone and the associated estradiol swings that make E2 management harder.

The 400 mg/mL concentration is a formulation choice, not a different compound. The carrier oil, solvent ratios (typically higher benzyl alcohol and benzyl benzoate to maintain oil clarity at the higher concentration), and the testosterone enanthate molecule itself are the same. The only pharmacological difference is that a given injection volume delivers 60% more testosterone than the same volume of the 250 mg/mL version. At doses of 600 mg/week and above, this reduction in injection volume is the primary practical reason to choose the 400 mg/mL format.

What Enantat 400 Does

At supraphysiological doses, testosterone enanthate produces the following effects — all of which are dose-dependent and identical regardless of the mg/mL concentration of the preparation used:

• Increased muscle protein synthesis and nitrogen retention — testosterone occupies androgen receptors in skeletal muscle, upregulating protein synthesis machinery and reducing nitrogen excretion; positive nitrogen balance is the mechanism behind lean mass accrual; the response is strongly dose-dependent across the 200–600 mg/week range and amplified significantly by resistance training.
• Strength and work capacity — androgen receptor activation in motor neurons and muscle tissue increases contractile force output; strength gains typically begin in weeks 3–4 as blood levels stabilize at steady state and compound through the duration of the cycle; at 600–800 mg/week the strength effect is substantially greater than at beginner-range doses.
• IGF-1 elevation — testosterone drives hepatic IGF-1 secretion, producing a secondary anabolic signal in muscle and connective tissue on top of the direct androgen receptor effect.
• Erythropoiesis — exogenous testosterone stimulates EPO production and acts directly on bone marrow precursor cells; hematocrit and hemoglobin rise on cycle; at the higher weekly doses typical of users choosing Enantat 400, hematocrit monitoring is more important than at lower doses.
• Libido, wellbeing, and recovery — above-physiological testosterone consistently improves sexual function, motivation, and training recovery; at high doses the wellbeing effect is pronounced but can be accompanied by increased aggression and sleep disruption in some users.
• Water retention — aromatase-mediated estradiol elevation in the first 4–6 weeks produces significant water and sodium retention; at the higher weekly doses common with Enantat 400 users, estradiol conversion is proportionally greater and AI management is correspondingly more important; water retention clears within 1–2 weeks post-cycle.

Who It Is For

Enantat 400 is not a beginner product. The 250 mg/mL concentration is the appropriate format for a first injectable cycle — the 400 mg/mL version offers no practical advantage at 350–500 mg/week (the beginner range), where injection volumes are already manageable, and its higher solvent content makes it more likely to cause injection site discomfort in users who have not yet developed injection technique and site rotation.

The 400 mg/mL format is relevant for:

• Intermediate and advanced users running 600–800+ mg/week who want to reduce injection volume — at 800 mg/week the difference is 2.0 mL per injection (400 mg/mL) versus 3.2 mL (250 mg/mL), which is a meaningful practical reduction in muscle tissue stress and injection time
• Athletes who have completed at least one testosterone cycle and understand how to manage estrogen, monitor bloodwork, and run PCT — the higher concentration does not change the management requirements, but running high-dose testosterone without that experience base creates unnecessary risk
• Blast-and-cruise users in a high-dose blast phase where Enantat 400 covers the blast period more conveniently than multiple 250 mg/mL injections
• Users who prefer twice-weekly injections and are running 600 mg/week — two injections of 0.75 mL is substantially less volume per site than two injections of 1.2 mL

Recommended Combinations

Enantat 400 covers the testosterone base for the same combination goals as Enantat 250, with dosing adjusted for the higher-concentration format. Dragon Pharma products throughout:

Side Effects & Management

The side effect profile of Enantat 400 is the same as any testosterone enanthate preparation. The higher-concentration format does introduce one additional consideration — injection site tolerability — which is covered below alongside the standard testosterone side effect categories.

PCT — Post-Cycle Therapy

PCT protocol for Enantat 400 is identical to Enantat 250 — the clearance window, SERM compounds, and dosing are determined entirely by the enanthate ester, not the carrier concentration. Start SERMs 14 days after the last Enantat 400 injection.

References